MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Author:
Affiliation:
1. Cardiovascular, Renal, and Metabolism iMED; MedImmune Ltd; Cambridge UK
2. Charité Research Organisation GmbH; Berlin Germany
3. Cardiovascular, Renal, and Metabolism iMED; MedImmune Inc; Gaithersburg MD USA
Funder
MedImmune
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13688/fullpdf
Reference30 articles.
1. Type 2 diabetes: principles of pathogenesis and therapy;Stumvoll;Lancet,2005
2. How to fight obesity with antidiabetic drugs: targeting gut or kidney?;Baretić;Minerva Endocrinol,2015
3. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group;Turner;JAMA,1999
4. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial;Douek;Diabet Med,2005
5. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial;Purnell;JAMA,1998
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis;Clinical Pharmacokinetics;2024-01-18
2. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes;European Journal of Pharmacology;2024-01
3. The role of glucagon after bariatric/metabolic surgery: much more than an “anti-insulin” hormone;Frontiers in Endocrinology;2023-08-11
4. Excess body weight: Novel insights into its roles in obesity comorbidities;Seminars in Cancer Biology;2023-07
5. The molecular pharmacology of glucagon agonists in diabetes and obesity;Peptides;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3